| Literature DB >> 31384448 |
Nish Arulkumaran1, Arunraj Navaratnarajah1, Camilla Pillay1, Wendy Brown1, Neill Duncan1, Adam McLean1, David Taube1, Edwina A Brown1.
Abstract
BACKGROUND: Patients who require acute initiation of dialysis have higher mortality rates when compared with patients with planned starts. Our primary objective was to explore the reasons and risk factors for acute initiation of renal replacement therapy (RRT) among patients with end-stage kidney disease (ESKD). Our secondary objective was to determine the difference in glomerular filtration rate (GFR) change in the year preceding RRT between elective and acute dialysis starts.Entities:
Keywords: acute dialysis start; renal replacement therapy; unplanned
Year: 2018 PMID: 31384448 PMCID: PMC6671523 DOI: 10.1093/ckj/sfy118
Source DB: PubMed Journal: Clin Kidney J ISSN: 2048-8505
Baseline characteristics of patients with planned, unplanned or urgent starts to RRT categorized by the cause for emergency presentation
| Planned | Unplanned | Urgent | Total | |||||
|---|---|---|---|---|---|---|---|---|
| Systemic illness | Accelerated decline | Patient related | Systemic illness | Accelerated decline | Patient related | |||
| Patients, | 410 | 135 | 81 | 28 | 106 | 57 | 8 | 825 |
| Age (years), mean (SD) | 61.9 (14.9) | 68.0 (11.4) | 63.3 (17.1) | 55.8 (16.8) | 63.9 (16.0) | 51.1 (18.3) | 68.9 (15.6) | 61.3 (15.8) |
| Time known to renal (years), mean (SD) | 5.0 (4.8) | 4.2 (4.2) | 3.0 (4.1) | 4.2 (4.5) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 3.6 (4.5) |
| Sex, | ||||||||
| Male | 256 (62.4) | 91 (67.4) | 49 (60.5) | 16 (57.1) | 69 (65.1) | 40 (70.2) | 2 (25.0) | 526 (63.2) |
| Female | 44 (32.6) | 32 (39.5) | 12 (42.9) | 37 (34.9) | 17 (29.8) | 6 (75.0) | ||
| Ethnicity, | ||||||||
| Asian | 188 (45.9) | 53 (38.5) | 33 (40.7) | 11 (39.3) | 32 (30.2) | 16 (28.1) | 4 (50.0) | 338 (40.6) |
| Black | 77 (18.8) | 24 (17.8) | 18 (22.2) | 7 (25.0) | 15 (14.2) | 19 (33.3) | 1 (12.5) | 163 (19.6) |
| Other | 21 (5.1) | 6 (4.4) | 5 (6.2) | 2 (7.1) | 2 (1.9) | 1 (1.8) | 0 (0.0) | 38 (4.6) |
| Caucasian | 124 (30.2) | 53 (39.9) | 25 (30.9) | 8 (28.6) | 57 (53.8) | 21 (36.8) | 3 (37.5) | 293 (35.2) |
| Primary renal diagnosis, | ||||||||
| Other | 62 (15.1) | 22 (16.3) | 8 (9.9) | 2 (7.1) | 35 (33.0) | 12 (21.1) | 3 (37.5) | 145 (17.4) |
| Unknown | 82 (20.0) | 19 (14.1) | 14 (17.3) | 6 (21.4) | 8 (7.5) | 22 (38.6) | 3 (37.5) | 155 (18.6) |
| Renovascular | 9 (2.2) | 7 (5.2) | 4 (4.9) | 0 (0.0) | 2 (1.9) | 2 (3.5) | 0 (0.0) | 24 (2.9) |
| Glomerulonephritis | 60 (14.6) | 15 (11.1) | 13 (16.0) | 4 (14.3) | 38 (35.8) | 2 (3.5) | 0 (0.0) | 134 (16.1) |
| ADPKD | 27 (6.6) | 3 (2.2) | 1 (1.2) | 2 (7.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 27 (6.6) |
| DM | 127 (50.4) | 69 (51.1) | 41 (50.6) | 14 (50.0) | 23 (21.7) | 19 (33.3) | 2 (25.0) | 170 (41.5) |
| Age range (years), | ||||||||
| <45 | 57 (13.9) | 5 (3.7) | 15 (18.5) | 7 (25.0) | 16 (15.1) | 24 (42.1) | 1 (12.5) | 127 (15.3) |
| 45–59 | 114 (27.8) | 23 (17.0) | 13 (16.0) | 10 (35.7) | 23 (21.7) | 12 (21.1) | 0 (0.0) | 197 (23.7) |
| 60–74 | 146 (25.6) | 65 (48.1) | 29 (35.8) | 7 (25.0) | 28 (26.4) | 13 (22.8) | 4 (50.0) | 294 (35.3) |
| >75 | 93 (22.7) | 42 (31.1) | 24 (29.6) | 4 (14.3) | 39 (36.8) | 8 (14.0) | 3 (37.5) | 214 (25.7) |
| DM, | 186 (45.4) | 91 (67.4) | 38 (59.3) | 15 (53.6) | 33 (31.1) | 22 (38.6) | 3 (37.5) | 402 (48.3) |
| Cardiac disease, | 86 (21.0) | 61 (45.2) | 23 (28.4) | 5 (17.9) | 31 (29.2) | 14 (24.6) | 2 (25.0) | 224 (26.9) |
| Cerebrovascular disease, | 30 (7.3) | 22 (16.3) | 6 (7.4) | 1 (3.6) | 9 (8.5) | 4 (7.0) | 1 (12.5) | 73 (8.8) |
| Peripheral vascular disease, | 34 (8.3) | 21 (15.6) | 13 (16.0) | 2 (7.1) | 10 (9.4) | 5 (8.8) | 1 (12.5) | 86 (10.3) |
| Viral disease, | 11 (2.7) | 6 (4.4) | 5 (6.2) | 2 (7.1) | 7 (6.6) | 6 (10.5) | 1 (12.5) | 38 (4.6) |
| Hypertension, | 103 (25.1) | 54 (40.0) | 35 (43.2) | 11 (39.3) | 48 (45.3) | 28 (49.1) | 6 (75.0) | 291 (35.0) |
| Haematological malignancy, | 10 (2.4) | 7 (5.2) | 3 (3.7) | 1 (3.6) | 8 (7.5) | 3 (5.3) | 1 (12.5) | 33 (4.0) |
| Biochemistry, | ||||||||
| Creatinine (μmol/L) | 672 (211) | 678 (240) | 767 (309) | 1001 (372) | 878 (482) | 1013 (589) | 790 (328) | 744 (335) |
| Modality, | ||||||||
| Peritoneal dialysis | 66 (16.1) | 1 (0.70) | 2 (2.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 69 (8.3) |
| Haemodialysis | 344 (83.9) | 134 (99.3) | 79 (97.5) | 28 (100.0) | 106 (100.0) | 57 (100.0) | 8 (100.0) | 763 (91.7) |
Data were complete for age, gender, planned status, mortality, initial RRT modality, primary renal diagnosis and reason for emergency RRT start. The following variables had missing data: ethnicity (n = 1), initial RRT access (n = 7), time known to renal services prior to RRT start (n = 13), creatinine (n = 1).
Reasons for initiation of RRT in patients with unplanned and urgent presentations to nephrology services
| Unplanned | Urgent | |||||
|---|---|---|---|---|---|---|
| Systemic illness | Unexpected decline | Patient related | Systemic illness | Unexpected decline | Patient related | |
| Patient related , | ||||||
| Non-compliance/non-attendance | – | – | 11 (39) | – | – | 0 (0) |
| Previous refusal of haemodialysis/conservative care | – | – | 13 (46) | – | – | 1 (13) |
| Drug toxicity (illicit/intentional) | – | – | 3 (11) | – | – | 3 (38) |
| Immigration, | – | – | 1 (4) | – | – | 4 (50) |
| Systemic illness, | ||||||
| Sepsis | 65 (48) | – | – | 28 (26) | – | – |
| Cardiovascular | 30 (22) | – | – | 11 (10) | – | – |
| Peripheral vascular disease | 4 (3) | – | – | 1 (1) | – | – |
| Autoimmunity | 6 (4) | – | – | 38 (36) | – | – |
| Major surgery | 14 (10) | – | – | 5 (5) | – | – |
| Obstructive uropathy | 3 (2) | – | – | 5 (5) | – | – |
| Other systemic causes with secondary renal involvement | 10 (7) | – | – | 14 (13) | – | – |
| Iatrogenic drug toxicity | 3 (2) | – | – | 4 (4) | – | – |
| Accelerated decline, | ||||||
| Accelerated decline (unplanned) | – | 81 (100) | – | – | – | – |
| Accelerated decline (urgent) | – | – | – | – | 57 | – |
| Total, | 135 | 81 | 28 | 106 | 57 | 8 |
FIGURE 1Proportion of patients requiring planned, unplanned and urgent initiation of dialysis.
Outcomes from regression analysis identifying risk factors for emergency commencement of RRT, expressed as unadjusted OR and CI with P-values to delineate significance at the P < 0.05 level
| Unplanned with systemic illness | Unplanned with unexpected decline | Urgent with systemic illness | Urgent with unexpected decline | |||||
|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | Sig. | OR (95% CI) | Sig. | OR (95% CI) | Sig. | OR (95% CI) | Sig. | |
| Sex | ||||||||
| Male | 1.15 (0.74–1.78) | 0.54 | 0.89 (0.54–1.48) | 0.65 | 1.18 (0.72–1.92) | 0.52 | 1.61 (0.83–3.13) | 0.16 |
| Reference: female | ||||||||
| Ethnicity | ||||||||
| Asian | 0.66 (0.41–1.08) | 0.10 | 0.97 (0.53–1.76) | 0.92 | 0.55 (0.32–0.93) | 0.03 | 0.47 (0.22–1.00) | 0.05 |
| Black | 0.90 (0.49–1.65) | 0.73 | 1.46 (0.72–2.49) | 0.30 | 0.64 (0.32–1.28) | 0.21 | 1.43 (0.66–3.09) | 0.36 |
| Other | 1.16 0.40–3.37) | 0.79 | 1.83 (0.59–5.63) | 0.30 | 0.31 (0.07–1.42) | 0.13 | 0.27 (0.03–2.31) | 0.23 |
| Reference: Caucasian | ||||||||
| Primary renal diagnosis | ||||||||
| Other | 2.85 (1.24–6.54) | 0.01 | 1.19 (0.38–3.78) | 0.77 | 4.48 (1.61–12.43) | 0.00 | 1.71 (0.39–7.56) | 0.48 |
| Unknown | 2.40 (0.96–5.06) | 0.06 | 2.09 (0.66–6.56) | 0.21 | 0.79 (0.23–2.74) | 0.71 | 4.09 (0.89–18.94) | 0.07 |
| Renovascular disease | 4.95 (1.12–21.89) | 0.04 | 3.91 (0.69–22.34) | 0.13 | 1.17 (0.16–8.81) | 0.88 | 9.29 (0.79–108.7) | 0.08 |
| Glomerulonephritis | 5.93 (0.46–77.07) | 0.17 | 1.41 (0.19–10.67) | 0.74 | 6.07 (2.10–17.56) | 0.001 | 0.14 (0.01–2.91) | 0.20 |
| ADPKD | 0.77 (0.19–3.20) | 0.72 | 0.33 (0.04–3.11) | 0.33 | NA | 0.99 | NA | 0.99 |
| Reference: diabetic nephropathy | ||||||||
| Comorbid illness | ||||||||
| DM | 5.42 (2.46–11.76) | 0.00 | 3.83 (1.34–10.99) | 0.01 | 1.39 (0.55–3.55) | 0.48 | 2.13 (0.50–9.01) | 0.31 |
| Cardiac disease | 1.96 (1.24–3.11) | 0.00 | 1.18 (0.65–2.14) | 0.59 | 1.59 (0.91–2.78) | 0.10 | 1.66 (0.76–3.61) | 0.20 |
| Cerebrovascular disease | 1.94 (1.03–3.66) | 0.04 | 0.85 (0.32–2.23) | 0.74 | 1.12 (0.52–2.83) | 0.66 | 0.98 (0.30–3.17) | 0.97 |
| Peripheral vascular disease | 1.24 (0.59–2.62) | 0.57 | 1.92 (0.81–4.55) | 0.14 | 1.62 (0.64–4.12) | 0.31 | 0.78 (0.20–3.00) | 0.71 |
| Viral disease | 1.46 (0.49–4.31) | 0.49 | 3.03 (0.97–9.34) | 0.06 | 2.28 (0.80–6.54) | 0.12 | 6.02 (1.86–19.23) | 0.00 |
| Hypertension | 1.69 (1.09–2.60) | 0.02 | 2.19 (1.32–3.65) | 0.00 | 2.53 (1.56–4.10) | 0.00 | 3.16 (1.91–6.80) | 0.00 |
| Haematological malignancy | 1.46 (0.50–4.26) | 0.49 | 1.55 (0.39–6.12) | 0.54 | 1.79 (0.63–5.08) | 0.28 | 1.66 (0.76–3.61) | 0.20 |
| Reference: no comorbid illness | ||||||||
| Age range (years) | ||||||||
| <45 | 0.28 (0.10–0.78) | 0.02 | 1.20 (0.54–2.65) | 0.66 | 2.13 (1.00–4.55) | 0.05 | 10.11 (3.65–28.0) | 0.00 |
| 45–59 | 0.47 (0.25–0.88) | 0.02 | 0.39 (0.18–0.84) | 0.02 | 2.19 (1.13–4.24) | 0.02 | 1.34 (0.47–3.80) | 0.59 |
| 60–74 | 0.93 (0.56–1.55) | 0.78 | 0.66 (0.35–1.26) | 0.21 | 2.56 (1.40–4.69) | 0.00 | 1.17 (0.43–3.15) | 0.76 |
| Reference: >75 | . | . | . | |||||
Sig., significance.
FIGURE 2Rate of change of eGFR in the 12 months preceding dialysis initiation. Data represent mean and standard mean error. Compared with planned starters, unplanned starters with systemic illness (−4.5 ± 0.9, P < 0.001), unplanned starters with accelerated unexpected decline in renal function (−3.6 ± 1.2, P = 0.029), urgent starters with systemic illness (−26 ± 1.5, P < 0.001) and urgent starters with unexpected accelerated decline in renal function (−13 ± 2.4, P < 0.001) had a greater rate of eGFR decline in the 12 months preceding dialysis.
Outcomes from regression analysis identifying risk factors for emergency commencement of RRT, expressed as adjusted OR and CI with P-values to delineate significance (sig.) at the P < 0.05 level
| Unplanned systemic illness | Unplanned unexpected decline | Urgent systemic illness | Urgent unexpected decline | |||||
|---|---|---|---|---|---|---|---|---|
| Adjusted OR (95% CI) | P-value | Adjusted OR (95% CI) | P-value | Adjusted OR (95% CI) | P-value | Adjusted OR (95% CI) | P-value | |
| Age | 1.02 (1.01–1.04) | <0.001 | 1.00 (0.99–1.02) | 0.67 | 1.01 (1.00–1.03) | 0.12 | 0.94 (0.92–0.96) | <0.01 |
| Comorbid illness | ||||||||
| DM | 5.40 (2.49–11.72) | <0.001 | 3.50 (1.25–9.87) | 0.02 | 1.32 (0.53–3.28) | 0.55 | 1.85 (0.43–7.86) | 0.41 |
| Cardiac | 2.11 (1.34–3.31) | <0.001 | 1.24 (0.69–2.22) | 0.47 | 1.80 (1.05–3.11) | 0.03 | 1.87 (0.87–4.01) | 0.11 |
| CVA | 1.83 (0.97–3.44) | 0.06 | 0.86 (0.34–2.21) | 0.76 | 1.17 (0.51–2.71) | 0.71 | 0.95 (0.30–3.07) | 0.94 |
| Vascular | 1.33 (0.64–2.75) | 0.45 | 1.83 (0.79–4.24) | 0.16 | 1.49 (0.60–3.68) | 0.39 | 0.77 (0.20–3.06) | 0.72 |
| Viral | 1.46 (0.50–4.24) | 0.49 | 2.40 (0.79–7.26) | 0.12 | 2.07 (0.75–5.75) | 0.16 | 4.85 (1.55–15.16) | 0.01 |
| HTN | 1.67 (1.09–2.56) | 0.02 | 2.02 (1.22–3.32) | 0.01 | 2.64 (1.54–3.95) | <0.01 | 3.26 (1.76–6.06) | <0.01 |
| Haematological malignancy | 1.24 (0.43–3.58) | 0.69 | 1.51 (0.38–5.97) | 0.56 | 1.62 (0.59–4.47) | 0.35 | 3.63 (0.81–16.32) | 0.09 |
| Reference: no comorbid illness | ||||||||
| Primary renal diagnosis | ||||||||
| Other | 2.98 (1.30–6.83) | 0.01 | 1.26 (0.40–3.92) | 0.69 | 4.73 (1.74–12.88) | <0.01 | 1.54 (0.34–6.93) | 0.57 |
| Unknown | 2.44 (0.99–6.01) | 0.05 | 2.16 (0.69–6.75) | 0.18 | 0.89 (0.26–3.02) | 0.86 | 3.96 (0.87–18.14) | 0.08 |
| Vascular | 4.53 (1.05–19.64) | 0.04 | 4.01 (0.71–22.52) | 0.12 | 1.34 (0.18–9.74) | 0.77 | 9.91 (0.81–120.77) | 0.07 |
| Autoimmune | 3.11 (1.23–7.87) | 0.02 | 2.63 (0.84–8.22) | 0.10 | 6.07 (2.13–17.27) | <0.01 | 0.28 (0.04–2.13) | 0.22 |
| ADPKD | 0.81 (0.20–3.33) | 0.77 | 0.32 (0.04–2.90) | 0.31 | NA | 1.00 | NA | . |
| Reference: DM | . | . | . | . | ||||
| Ethnicity | ||||||||
| Asian | 0.69 (0.43–1.12) | 0.13 | 0.89 (0.49–1.61) | 0.70 | 0.52 (0.31–0.89) | 0.02 | 0.40 (0.19–0.84) | 0.02 |
| Black | 0.89 (0.49–1.62) | 0.70 | 1.30 (0.55–2.60) | 0.46 | 0.62 (0.32–1.24) | 0.18 | 1.16 (0.55–2.45) | 0.70 |
| Other | 1.06 (0.37–3.05) | 0.92 | 1.65 (0.55–4.96) | 0.38 | 0.30 (0.07–1.36) | 0.12 | 0.23 (0.03–1.89) | 0.17 |
| Reference: White | . | . | . | . | ||||
| Gender | ||||||||
| Male | 1.07 (0.69–1.64) | 0.78 | 0.85 (0.52–1.41) | 0.54 | 1.12 (0.70–1.81) | 0.64 | 1.57 (0.82–3.02) | 0.18 |
| Reference: female | . | . | ||||||
Adjusted for age, sex, primary renal diagnosis, ethnicity and comorbid illness.
Reference category is planned.
No patients with ADPKD in this category.